GuCS

KEYNOTE-057 trial results suggest DFS benefit for patient population with unmet need

But add-on abiraterone and apalutamide may offer some benefits in those with higher PSA

Final PROpel analysis also shows trend toward overall survival improvement with PARP inhibitor

Combination achieved a 37% reduction in risk of progression, death versus ARPI alone

Benefit in selected patients seen over physician's choice of docetaxel or second-generation ARPI

Atezolizumab did show some activity, with a 30% overall response rate

Early-phase study offers 36% pCR in cisplatin-ineligible patients with muscle-invasive disease

Docetaxel-enzalutamide regimen may offer another option for men who progressed on AR inhibitor

In one case, rPFS benefit was seen regardless of HRR mutational status

The AR inhibitor plus standard therapy led to a 32% reduced risk of death versus placebo

Pembrolizumab-lenvatinib makes splash with longest PFS benefit in RCC recorded to date

Cabozantinib improved PFS, response rates over sunitinib

Adjuvant nivolumab improves DFS in all comers, PD-L1 population

Large proportion of intermediate- to high-risk patients could avoid aggressive therapy